Acadia Pharmaceuticals
ACAD · Pharmaceuticals
$19.73
2.9%Corcept Therapeutics
CORT · Pharmaceuticals
$85.86
20.1%The short version
- Acadia Pharmaceuticals is the larger business, with $1.1B of revenue in fiscal 2025 against $761M for Corcept Therapeutics.
- Corcept Therapeutics grew revenue faster (12.8%, against 11.9%).
- Acadia Pharmaceuticals kept more of each dollar of sales as operating profit (9.8% operating margin, against 5.9% operating margin).
- Corcept Therapeutics turned more of its sales into free cash flow (18.6% FCF margin, against 9.8% FCF margin).
| Latest fiscal year | ACAD · FY25 | CORT · FY25 |
|---|---|---|
| Size | ||
| Market cap | $3.4B | $10.2B |
| Revenue | $1.1B | $761M |
| Free cash flow | $105M | $142M |
| Net income | $391M | $99.7M |
| Growth | ||
| Revenue growth | 11.9% | 12.8% |
| 5-year growth | 19.4% | 16.6% |
| Share count change | 2.1% | 5.7% |
| Profitability | ||
| Gross margin | 91.7% | 98.3% |
| Operating margin | 9.8% | 5.9% |
| Net margin | 36.5% | 13.1% |
| FCF margin | 9.8% | 18.6% |
| Return on capital | — | 15.7% |
| Return on equity | 39.9% | 15.0% |
| Balance sheet | ||
| Net debt | — | −$372M |
| Net debt / EBITDA | — | −8.1x |
| Dividends and buybacks | $0.0M | $173M |
| Valuation & quality | ||
| P/E | 8.9x | — |
| Piotroski F-score | — | 3 |
FY16
ACAD $17.3M
CORT $81.3M
FY17
ACAD $125M
CORT $159M
FY18
ACAD $224M
CORT $251M
FY19
ACAD $339M
CORT $307M
FY20
ACAD $442M
CORT $354M
FY21
ACAD $484M
CORT $366M
FY22
ACAD $517M
CORT $402M
FY23
ACAD $726M
CORT $482M
FY24
ACAD $958M
CORT $675M
FY25
ACAD $1.1B
CORT $761M
ACAD
CORT
FY16
ACAD −1,574.1%
CORT 12.5%
FY17
ACAD −234.1%
CORT 33.2%
FY18
ACAD −110.6%
CORT 35.6%
FY19
ACAD −72.7%
CORT 36.4%
FY20
ACAD −64.9%
CORT 36.2%
FY21
ACAD −35.2%
CORT 34.0%
FY22
ACAD −43.2%
CORT 28.0%
FY23
ACAD −10.1%
CORT 22.2%
FY24
ACAD 24.1%
CORT 20.3%
FY25
ACAD 9.8%
CORT 5.9%
ACAD
CORT
FY16
ACAD −$210M
CORT $18.2M
FY17
ACAD −$219M
CORT $60.5M
FY18
ACAD −$170M
CORT $115M
FY19
ACAD −$152M
CORT $135M
FY20
ACAD −$144M
CORT $151M
FY21
ACAD −$127M
CORT $167M
FY22
ACAD −$114M
CORT $120M
FY23
ACAD $16.7M
CORT $127M
FY24
ACAD $157M
CORT $196M
FY25
ACAD $105M
CORT $142M
ACAD
CORT
FY16
ACAD —
CORT —
FY17
ACAD —
CORT 99.0%
FY18
ACAD —
CORT 85.5%
FY19
ACAD —
CORT 109.6%
FY20
ACAD —
CORT 116.1%
FY21
ACAD —
CORT 95.4%
FY22
ACAD —
CORT 88.4%
FY23
ACAD —
CORT 87.6%
FY24
ACAD —
CORT 55.1%
FY25
ACAD —
CORT 15.7%
ACAD
CORT
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.